Foundation for Adenosine Research
Nonprofit profile at a glance
- EIN
- 394648664
- IRS 990-EZ coverage
- 2025–2025
- Forms available
- Form 990-EZ 2025
- Location
- Charlottesville, VA, USA
- Phone
- 4342260683
- Rating
- 46
- Verdict
- MIXED
- Rating confidence
- Moderate
- Sector
- Research Institutes and Public Policy Analysis
Reported finances
- Revenue
- $75,000
- Expenses
- $45,655
- Assets
- $29,345
- Liabilities
- $0
Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
5 people listed
Executive titles in this filing
- Uday Gupta (President & Treasurer)
People named in this filing
- William Stilley (Director)
- J Kermit Anderson (Director)
- James Newman (Director)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
To advance scientific understanding and innovation in the field of adenosine biology by supporting the exploration of adenosine's role in human health and disease, fostering collaboration across disciplines, and accelerating discoveries into transformative therapies for the benefit of patients and society, as well as the making of distributions to organizations that qualify as exempt organizations under the Internal Revenue Code.
What it reported doing in 2025
Research Grantmaking and Scientific Program Support. 70 percent of total activity and 85-88 percent of expenses. FAR awards research grants and provides targeted financial support for early stage scientific investigations in adenosine biology. Grants are designed to support hypothesis-driven preclinical and translational research, including pilot studies, proof-of-concept experiments, and data generation necessary to advance understanding of adenosine signaling in areas such as oncology, autoimmune disease, inflammation, and metabolic disorders. Scientific review and funding recommendations are supported by external scientific advisors and, beginning in 2026, a formal Scientific Advisory Council composed of independent subject-matter experts who serve as unpaid volunteers. Funded research activities are conducted at third-party academic institutions, nonprofit research organizations, and qualified research laboratories in the US. FAR does not operate laboratory facilities. Activity is funded entirely through charitable donations. Expenses are allocable to research grants, pilot studies, and associated scientific program support. Activity directly furthers FAR's scientific and educational purposes by advancing basic and translational research related to adenosine biology. Funding early stage research reduces barriers to discovery, promotes dissemination of scientific knowledge, and accelerates progress toward therapies that benefit public health.
Operating model
- Revenue model
- Donor-supported. 100% of the money available for current operations came from contributions and gifts.
- Distribution model
- Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.
The verdict
MIXED - The filed numbers largely add up and revenue comfortably covers expenses. A relatively small share of available resources goes toward mission work and a relatively small share of total spending goes to programs.
Rating breakdown
- Financial Efficiency: 5
- Transparency & Controls: 100
- Sustainability: 65
- Growth: NotEnoughData
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 4.2%; rating input score 4
- Program expense ratio: 6.9%; rating input score 7
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 51st percentile among comparable filings
- Major donor itemization: Yes; rating input score 100
Sustainability
- Operating margin: 39.1%; rating input score 85; 85th percentile among comparable filings
- Total-asset coverage ratio: 0.64; rating input score 37; 37th percentile among comparable filings
- Liabilities to assets ratio: 0; rating input score 66; 66th percentile among comparable filings
- Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: Limited
- Asset growth: Limited
Details
- Where the money goes: 4.2% of revenue deployed · 6.9% of spending went to programs
- Governance: Filed governance answers
- Accomplishments: 4 filed program accomplishments · $3K in reported program spending
- Leadership: top reported pay $0 · 5 people listed
- Consistency: 8 of 9 current checks pass · 1 finding to review
- Schedules: 2 filed schedules
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Financial Efficiency: Mission deployment rate scored 4/100.
- High — Financial Efficiency: Program expense ratio scored 7/100.
- Moderate — Transparency & Controls: Part III transfer expenses within program total did not reconcile in the filed values.
- Moderate — Sustainability: Total-asset coverage ratio scored 37/100.
- Review — Sustainability: Officer compensation ratio scored 56/100.